Market Overview

Citron Compares Express Scripts To Philidor: 'Culprit Behind Pharmaceutical Price Gouging'

Share:
Citron Compares Express Scripts To Philidor: 'Culprit Behind Pharmaceutical Price Gouging'

The culprit behind price gouging?

In tweets sent out Thursday directed at President-elect Donald Trump, Citron Research targeted pharmacy benefit giant Express Scripts Holding Company (NASDAQ: ESRX), referring to the company as "the Philidor of the pharma industry," and setting a $45 price target for the stock.

Back in October 2015, the short-seller published a "smoking gun" detailing what it calls a "cover up" concerning Valeant's relationship with specialty pharma company Philidor RX.

An Express Scripts spokesperson told Benzinga, "We clearly disagree with [Left's] assertions. We are not at all like Philidor. Express Scripts is a market force that uniquely puts medicine within reach by driving down cost of care and improving health outcomes."

screen_shot_2016-12-08_at_1.15.27_pm.png

screen_shot_2016-12-08_at_1.15.43_pm.png

screen_shot_2016-12-08_at_1.16.11_pm.png

Since the tweets went out, shares of Express Scripts are down over 6 percent at $69.36.

CVS Health Corp (NYSE: CVS) also fell, trading recently at $77.97, down 3 percent.

Posted-In: Citron Research PhilidorNews Short Sellers Health Care Movers General Best of Benzinga

 

Related Articles (ESRX + CVS)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Tailored Brands Still Surging After Q3 Earnings

Starbucks' Investor Day Proves Company Remains A Global Growth Story